Sentence examples for examples of mutant from inspiring English sources
There are also many examples of mutant strains expressing virtually identical phenotypes as their wild-type controls, causing concern regarding the appropriateness of these models for the study of physiological processes.
There are very few examples of mutant alleles containing defects in the LRR regions that occur before the 70-amino acid island.
Examples of calculated values are shown in the inset in Figure 7C. Figure 7C and 7D show examples of mutant models that differ in their relative division rates.
We found that, like in integrin α5-null mutants, the presumptive notochordal cells originated from either corner of the anterior-facing mutant node (Fig. 1E,F, two different examples of mutant nodes are shown).
However, there are few examples of mutant proteins being used to activate the HSR, despite the conventional wisdom that the HSR responds to unfolded proteins (Wolff et al., 2014).
Indeed, this may be the case and there are examples of mutant mice that display both enhanced SC LTP in vitro and enhanced performance in the Morris water maze task (a hippocampal-dependent spatial memory task) (Malleret et al., 2001; Chen et al., 2003).
Secondly, there are several examples of mutants in which Purkinje cells are ectopic but still express an appropriate phenotype (e.g., zebrin II-immunopositive/HSP25-immunopositive from the CZ in weaver 40; zebrin II-immunonegative/PLCß4-immunopositive Purkinje cells from the AZ in cdf 41).
E1A and K10A are examples of mutants that produce weak perturbations in Kd (∆∆G < 1 kcal mol−1), while W8A and W28A are examples of mutants that have larger perturbations (∆∆G > 2 kcal mol−1).
However, these relationships were not absolute as we found examples of mutants with moderate aggregation propensity in which disease duration is shorter than 10 years: I113T and L144F see1 (Supplementarytary Material, Table S1, Fig. 5).
Whether these exceptions are truly examples of mutants that aggregate slowly and yet are associated with rapidly progressing disease (e.g. D101N mutant) or mutants that aggregate rapidly and yet are associated with slowly progressing disease (e.g. E100K) is uncertain.
